• Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Commitment to sport
  • Research
    • Pharmaceutical Research
    • Sucrosomial Technology
    • Cetylated Fatty Acids
    • Quality and certifications
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • SiderAL Med
      • Cetilar Crema
      • Cetilar Patch
      • Cetilar Tape
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor
    • INVESTOR RELATIONS
      • Stock performance
      • Share capital and Shareholders
      • Shares study and research
      • Broker
      • Financial statements
      • Presentations
      • Corporate events
      • Company presentation
      • Notice of meetings
      • SDIR
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Code of Ethics
    • 231 Model
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • News
    • Science
    • Corporate
    • Events
    • Social commitment
  • Careers
    • Work with us
    • Job offers
    • Job application
  • Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Commitment to sport
  • Research
    • Pharmaceutical Research
    • Sucrosomial Technology
    • Cetylated Fatty Acids
    • Quality and certifications
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • SiderAL Med
      • Cetilar Crema
      • Cetilar Patch
      • Cetilar Tape
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor
    • INVESTOR RELATIONS
      • Stock performance
      • Share capital and Shareholders
      • Shares study and research
      • Broker
      • Financial statements
      • Presentations
      • Corporate events
      • Company presentation
      • Notice of meetings
      • SDIR
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Code of Ethics
    • 231 Model
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • News
    • Science
    • Corporate
    • Events
    • Social commitment
  • Careers
    • Work with us
    • Job offers
    • Job application
  • it
  • en

10 March 2020 |

PHARMANUTRA S.P.A SUPPORTING THE NATIONAL HEALTH SERVICE IN THIS EMERGENCY

Download the Press Release

PharmaNutra Spa

Registered office

Via Delle Lenze, 216/b - 56122 Pisa

Phone +39 050 7846500

Fax +39 050 7846524

Electronic billing code

SUBM70N

C.F. / P.Iva / Reg. Impr. 01679440501

Share capital € 1.123.097,70

I.V. | REA 146259

Contacts

Info
info@pharmanutra.it
Commerciale
commerciale@pharmanutra.it
Investor relations
investorrelation@pharmanutra.it
Distribution
internationaldept@pharmanutra.it

Product sites

sideral.it

cetilar.it

ultramag.it

apportal.it

NEWSLETTER

Subscribe to the Pharmanutra newsletter and you will be constantly updated on all our activities.
Read Newsletter Disclosure

Subscribe to the newsletter
Privacy policy Cookie policy General conditions PRIVACY INFORMATION FOR CUSTOMERS

© 2022 2020 PharmaNutra SpA - All rights reserved